Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
In Reply: We have previously addressed the
issues raised by Drs Pèrez-Molina and Fernández.1
As we have stated, resistance testing (genotypic as well as phenotypic) should
be viewed in the context of many other factors when choosing drug therapy.
Such factors include treatment history, viral load, medication tolerance,
adherence, and concomitant medical conditions. Pèrez-Molina and Fernández
raise a theoretical concern regarding linkage of mutations that we have discussed
previously1 and that may apply to phenotyping
as well as genotyping.
Hirsch MS, Richman DD. The Role of Genotypic Resistance Testing in Selecting Therapy for HIV—Reply. JAMA. 2000;284(13):1649–1650. doi:10.1001/jama.284.13.1647
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.